Global 5-Alpha Reductase Deficiency Market – Industry Trends and Forecast to 2030

5-Alpha Reductase Deficiency Market Analysis and Size

5-alpha-reductase deficiency is a major cause of ambiguous genitalia in children. This is a rare disorder observed most commonly because of a mutation in the gene SRD5A2 located on the short arm of chromosome. Up to 40 different types of mutations have been witnessed leading to this disease. Consequently, male differentiation does not occur throughout foetal development despite high amounts of testosterone in the blood.

Data Bridge Market Research analyses a growth rate in the 5-alpha reductase deficiency market in the forecast period 2023-2030. The expected CAGR 5-alpha reductase deficiency market is around 7.30% in the mentioned forecast period. The market is valued at USD 1.16 billion in 2022, and it will grow upto USD 2.04 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

5-Alpha Reductase Deficiency Market Scope and Segmentation

Market Definition

 5-alpha-reductase deficiency is a type of congenital disease which affects male sexual development. This disorder causes children to appear female at birth, but later they will grow male genitalia during adolescence. The main worry for male patients is to continue the testis for later hormone production. For patients who were raised as females, the possible surgical options are early removal of gonadal tissue to prevent masculinization before puberty, surgical correction of the external genitalia, clitoral reduction, and cyclic hormonal therapy at puberty

5-Alpha Reductase Deficiency Market Dynamics

Drivers

• Increase in the 5-alpha reductase deficiency cases

The growing number of cases of 5-alpha reductase deficiency is a main factor which is driving the market growth rate during the forecast period. Ambiguous genitalia is an unusual condition in infants, which is occurring in 1 out of every 4500 live births. It has been witnessed that only 20 to 40% of the time these youngsters can be diagnosed with these condition. Thus, this incidence is leading the market growth.

• Demand of Treatment Options

There are varied surgical options that are increasing the growth of the market. The surgical correction available if the child chooses to be a female is external genitalia reconstruction, creating a vaginal opening in the perineum with a clear separation of the urethra and vagina. In the teenage time, vaginoplasty would be the ultimate treatment option. Corrective surgery should be done depending on the phenotype of the child if the child is raised as a male. This boosts the market growth.

Opportunities

• Diversified Diagnostic Tests

Conventionally, the biochemical test of choice for diagnosing 5 alpha-RD2 enzyme deficiency has been the point of estimating the ratio between testosterone to DHT after stimulation with human chorionic gonadotropin. Another way of diagnosis is gene analysis. The human gene SRD5A2 gene demands a protein that makes up enzyme 5alpha-RD2 containing 254 amino acids. At least 54 diverse types of mutations have been witnessed involving with this gene, among which the primary type is missense mutations. Thus, these tests demand the growth of the market.

Restraints/Challenges

• High Cost of Treatment Process

The huge expenditure needed for the various surgical options hampers the market growth. Many market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.

• Failure of Detection by Biochemical Assay

This test is not very reliable as the ratio of testosterone to DHT may vary based on numerous factors such as age of the children and severity of enzyme deficiency. This biochemical test is also not very useful in case of partial enzyme deficiencies.

This 5-alpha reductase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the 5-alpha reductase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global 5-Alpha Reductase Deficiency Market Scope

The 5-alpha reductase deficiency market is segmented on the basis of diagnosis, treatment, age of onset, end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Chromosome Analysis
• Gene Sequencing
• Hormone Tests
• Imaging Tests
• Genetic Screening
• Others

Treatment

• Surgery
• Hormone Replacement Therapy
• Others

Age of Onset

• Childhood
• Neonatal
• Infancy
• Adolescent

End-Users

• Hospitals
• Specialty Clinics
• Others

5-Alpha Reductase Deficiency Market Regional Analysis/Insights

The 5-alpha reductase deficiency market is analyzed and market size insights and trends are provided by diagnosis, treatment, age of onset, end-user as referenced above.

The major countries covered in the 5-alpha reductase deficiency market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market because of the increasing incidence of 5-alpha reductase deficiency and growing healthcare expenditure will boost the market growth rate in this region.

Asia-Pacific is considered to grow over the coming years because of the development of healthcare infrastructure in this region. Furthermore, increasing government initiatives will further boost the market growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global 5-Alpha Reductase Deficiency Market Share Analysis

The 5-alpha reductase deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to 5-alpha reductase deficiency market.

Key players operating in the 5-alpha reductase deficiency market include:

• Alma Lasers (Israel)
• LUTRONIC (South Korea)
• ThermiGen, LLC. (U.S.)
• Viveve Solutions (U.S.)
• Fotona (Slovenia)
• Almirall, S.A (Spain)
• Hologic, Inc. (U.S.)
• Abbvie, Inc (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Merck KGaA (Germany)
• Novo Nordisk A/S (Denmark)
• Abbott (U.S.)

SKU-68373